<DOC>
	<DOC>NCT01902121</DOC>
	<brief_summary>A Phase 1, open-label, randomized, crossover study in 36 healthy normal volunteers (HNVs) to evaluate the bioequivalence of TI Inhalation Powder delivered using the Gen2 Inhaler and administered as one 30 U cartridge versus a combination of one 10 U cartridge and one 20 U cartridge.</brief_summary>
	<brief_title>Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Men and women aged 18 to 45 years, considered healthy based on screening physical examination, medical history, clinical chemistry, and urinalysis No smoking in the past 6 months (including cigarettes, cigars, and pipes) Urine cotinine testing &lt; 100 ng/mL Body mass index &lt; 32 kg/m2 Completion of informed consent form FBG &gt; 100 mg/dL Clinically significant active or chronic illness History of asthma, chronic obstructive pulmonary disease (COPD), or any other clinically relevant chronic lung disease Respiratory tract infection within 4 weeks before screening and between the screening visit and dosing visit Subjects who are experiencing persistent or recurring cough, wheezing, bronchospasm, or dyspnea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>